Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: New Zealand,Singapore,United Kingdom,Russian Federation,Croatia,Portugal,Finland,Ireland,Taiwan, Province of China - Phase: complete
nct
Update Il y a 5 ans
Efficacy and Safety of Oral Roflumilast Taken With Low Dose Inhaled Corticosteroids in Patients With Asthma (12 to 70 y) (BY217/M2-013)
Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma. The aim of the study is to investigate the effect of roflumilast taken orally together with low dose inhaled corticosteroids on lung function. Roflumilast will be administered at one dose level once daily together with inhaled corticosteroids at one dose level twice daily. The study duration consists of a baseline period (2 to 6 weeks) and a treatment period (24 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.
Country
Austria
,
Croatia
,
Czech Republic
,
Finland
,
France
,
Greece
,
Hungary
,
India
,
Ireland
,
Italy
,
New Zealand
,
Norway
,
Pakistan
,
Philippines
,
Poland
,
Portugal
,
Russian Federation
,
Singapore
,
South Africa
,
Spain
,
Taiwan, Province of China
,
Thailand
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1